Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California Q1 Earnings Call Highlights
Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.71, marking a -1.16% move from the previous day.
PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing
PACB stock rises after unveiling a new FFPE workflow with Covaris, boosting HiFi sequencing accuracy and unlocking insights from archived tumor samples.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.6, marking a +1.91% move from the previous day.
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.44, moving +1.41% from the previous trading session.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ongoing purchasing cycle challenges.
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
